Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Conditions
Autism
Interventions
DMXB-A 150 mg, placebo, DMXB-A 75 mg
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Alzheimer Disease
Interventions
DMXB-A
Drug
Lead sponsor
CoMentis
Industry
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
280 South San Francisco, California
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Dimethoxybenzylidene anabaseine (DMXB-A), Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 2 Interventional Results available

Nicotinic Receptors and Schizophrenia

NCT01400477
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DMXB-A-SR, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado
Withdrawn Phase 1Phase 2 Interventional

Nicotinic Receptors and Schizophrenia

NCT02538081
Conditions
Schizophrenia
Interventions
Risperidone plus Placebo, Risperidone plus DMXB-A
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Receptors and Schizophrenia

NCT00952393
Conditions
Schizophrenia
Interventions
Pharmacokinetic
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 2 Interventional Results available

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165
Conditions
Schizophrenia
Interventions
Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Agonist Effects on BMI and Neuronal Response

NCT02458313
Conditions
Obesity
Interventions
DMXB-A, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Denver, Colorado